Lilly Eli & Co SEC Filings

Lilly Endowment Inc., a director-related reporting person, sold a total of 10,602 shares of Eli Lilly & Co common stock on 10/09/2025. The Form 4 lists eight separate sale entries with weighted-average prices for each block; the reported trade price ranges span from $848.09 up to $857.26. After these transactions, the reporting person beneficially owns 94,536,978 shares directly. Each sale line notes the reporting person can provide detailed per-price quantities on request, and the Form 4 was signed by Peter A. Buck on behalf of Lilly Endowment Inc.

Form 144 notice for Eli Lilly & Co (LLY) records a proposed sale of 305,000 shares of Common Stock through J.P. Morgan Securities LLC with an aggregate market value of $260,881,750 and an approximate sale date of 10/10/2025. The filing lists 946,456,759 shares outstanding for the class. The shares to be sold were acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, showing an original acquired amount of 38,400,000 shares.

The notice also discloses multiple recent sales by Lilly Endowment Inc., including 280,000 shares sold on 07/24/2025 for $225,419,292 and a series of sales from 09/18/2025 through 10/09/2025 with individual proceeds reported. The signer certifies no undisclosed material adverse information and complies with Rule 144 procedural disclosure.

Lilly Endowment Inc. reported the sale of 101,420 shares of Eli Lilly & Co. (LLY) on 10/08/2025 via multiple transactions at weighted-average prices in the range of $848.00 to $856.00. After these disposals, the reporting person shows beneficial ownership of 94,547,580 shares, held indirectly. The filing is a standard Section 16 Form 4 showing routine disposition activity by an entity identified as a director-related reporting person; the signature is provided by a vice president acting on behalf of the endowment.

Lilly Endowment Inc. reported a sale of 26,795 shares of Eli Lilly & Co. common stock on 10/07/2025. The shares were sold at a weighted average price of $848.009, with individual trade prices ranging from $848.00 to $848.32. After the transaction the reporting person beneficially owned 94,649,000 shares, held directly. The Form 4 was signed by Peter A. Buck on 10/08/2025. The filing discloses no derivative holdings and includes an offer to provide a breakdown of the number of shares sold at each price within the reported range.

Lilly Endowment Inc., a reporting person and director-related holder, sold a total of 161,183 shares of Eli Lilly & Co (LLY) on 10/06/2025. The Form 4 lists eight separate sale line items with weighted-average prices reported in footnotes, ranging across price bands from $848.00 up to $856.375. After these transactions, the reporting person’s beneficial ownership is shown as 94,675,795 shares (reported as direct ownership). The Form 4 is signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc., and discloses that full per-price breakdowns are available upon request.

Lilly Endowment Inc. reported multiple open-market disposals of Common Stock of Eli Lilly & Co (LLY) executed on 10/03/2025. The filings list a sequence of sales that reduced beneficial ownership from 95,025,096 shares to 94,836,978, a net decrease of 188,118 shares. Individual sale lots ranged from 200 to 31,102 shares at reported weighted-average prices in successive buckets from $821.00 up to $847.63, with explanatory footnotes showing transaction price ranges within each bucket. The Form 4 is signed by Diane M. Stenson on behalf of Lilly Endowment Inc.

Eli Lilly & Co (LLY) submitted a Form 144 notice reporting a proposed sale of 300,000 shares of common stock through Fidelity Capital Markets with an indicated aggregate market value of $251,961,000 and an approximate sale date of 10/06/2025 on NYSE/NASDAQ.

The filing shows these shares were originally received as a gift on 02/10/1948 from the J.K. Lilly Sr. Trust. The document also lists multiple prior sales by Lilly Endowment Inc. during 07/24/2025–10/03/2025 that together generated substantial gross proceeds (individual entries up to $284,653,451.48). The signer certifies no undisclosed material adverse information.

This Schedule 13G/A reports that Eli Lilly & Co. and Eli Lilly S.A. filed an amendment concerning their holdings in Immunocore Holdings plc ordinary shares (CUSIP 54258D105) related to the reporting event dated 09/30/2025. Both reporting entities state they beneficially own 0 ordinary shares, representing 0.0% of the class, with 0 shares of sole or shared voting or dispositive power. The filing lists issuer headquarters at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, UK. Signatures show the amendment was executed by Christopher Anderson as Attorney-in-Fact for both filers on 10/03/2025, and reference previously filed powers of attorney incorporated by reference.

Lilly Endowment Inc. reported the sale of 112,596 shares of Eli Lilly & Co. (LLY) common stock on 10/02/2025. The Form 4 lists multiple sale (S) transactions with weighted-average prices reported per line ranging from about $821.09 to $833.92 and transaction price ranges across the trades between $821.00 and $834.23. After the reported sales, the filing shows the reporting person beneficially owned 95,029,382 shares, held directly. The form is signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc., dated 10/03/2025. The filing provides weighted-average prices and footnotes saying the filer will supply per-price breakdowns on request.